Novo Nordisk Stock Jumps on Upgrade to 'Buy'

Company Performance and Market Reaction - Novo Nordisk's U S-listed shares rose 3 5% premarket following a bullish note from UBS [1] - The stock has declined 40 7% over the past six months, exacerbated by a nearly 20% drop in late December due to updates on its weight loss drug CagriSema [1] - The 14-day relative strength index (RSI) of 15 4 indicates the stock is "oversold," signaling potential rebound opportunities [1] Analyst Commentary and Upgrades - UBS upgraded Novo Nordisk to "buy" from "neutral," citing strong demand for GLP-1 medications [1] - The company is described as "the most exciting growth story in European pharma" by the analyst [1] Options Market Insights - Novo Nordisk's Schaeffer's Volatility Index (SVI) of 33% is in the 11th percentile of its annual range, suggesting lower-than-usual volatility expectations [2] - Options may be an attractive choice for investors considering the current volatility levels [2]